Clinical trial Recruiting at 1 site Observational Ages 16 and up

Turkish version of the Nottwil Environmental Factors Inventory for people with spinal cord injury

Official title: Turkish Translation and Content Validity of the Nottwil Environmental Factors Inventory (NEFI) in Persons With Spinal Cord Injury

Run by Istanbul Medeniyet University · NCT07368244 · Data updated 2026-11-12

This project will create and test a Turkish Nottwil Environmental Factors Inventory with adults in Turkey who have spinal cord injury to make sure each question is clear and culturally appropriate.

More Spinal Cord Injuries (SCI) trials

Quick facts

Study typeObservational
Ages16 Years and up
SexAll
Enrollment405 (estimated)
SponsorIstanbul Medeniyet University
Academic / other
Locations1 site (Istanbul)
StatusRecruiting
StartedJanuary 1, 2026
Main results expectedFebruary 1, 2026
Study endsFebruary 5, 2026
Registry record updatedJanuary 26, 2026
Trial IDNCT07368244 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults aged 16 and older who live in Turkey, can read and understand Turkish, have a history of spinal cord injury, and are clinically stable enough to complete questionnaires are ideal candidates.

Probably not a fit

People fully recovered from their spinal cord injury, those with severe cognitive or communication impairments, or anyone judged by investigators to be unable to participate would likely not benefit from this effort.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The project uses a standardized translation and cultural adaptation process to produce a Turkish NEFI (NEFI-TR), including two independent forward translations, reconciliation by a multidisciplinary committee, and independent back-translation. An expert committee will review items for semantic, idiomatic, experiential, and conceptual equivalence, with optional cognitive debriefing interviews with adults with spinal cord injury to check clarity and relevance. Final revisions, proofreading, and full documentation of decisions will be completed, aiming to finalize the NEFI-TR within one month.

Why it matters

Potential benefit: If successful, patients could have a validated Turkish questionnaire that better captures environmental factors affecting life after spinal cord injury, supporting improved care planning and research.

How similar studies have gone: Cross-cultural translations and content-validity processes for patient-reported measures are common and have often produced reliable localized instruments, so the method is well-established though results depend on execution.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Adults (\>=16 years) with a diagnosis/history of spinal cord injury (traumatic or non-traumatic)
* Living in Turkey
* Able to read/understand Turkish and provide informed consent
* Clinically stable to complete questionnaires

Exclusion Criteria:

* Fully recovered from SCI / no longer living with SCI-related functional consequences (as defined by your protocol)
* Severe cognitive/communication limitations preventing valid completion
* Any condition judged by investigators to preclude participation

Where it's running

  • Istanbul Medeniyet University Goztepe Prof Dr Suleyman Yalcin City Hospital
    Istanbul, Turkey (Türkiye)
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.